Molecular profiling of diseases identifies specific cancer-causing genes and associated networks. Administered drug displays different therapeutic efficiency depending on individual cancer subtype and therapeutic responses. Personalized medicine helps designing treatment methods for individual patients with distinct diseases. For complete understanding of patient’s pathophysiology, different omics data types are integrated. These data can be derived from whole-exome sequencing, metabolomics, pharmacogenomics, and proteomics. Pharmacogenomics deals with the interaction of drug and patient’s genetic make-up and metabolomics reveals custom regulation of biochemical pathways in patients. Transcriptomics and proteomics analyze organism tissue or cell type in cancer and play even more relevant role in personalized medicine. Since associated genetic anomalities and metabolic profiles influence therapy response, a continuous evolution of cancer nanotheranostics helps preventing and treating the disease more precisely.